Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Exelixis, STORM Therapeutics enter license agreement » 08:31
10/14/21
10/14
08:31
10/14/21
08:31
EXEL

Exelixis

$21.46 /

+0.065 (+0.30%)

Exelixis and STORM…

Exelixis and STORM Therapeutics announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. Under the terms of the agreement, Exelixis will pay STORM an upfront fee of $17M in exchange for licensing two of STORM's discovery programs targeting RNA modifying enzymes, including ADAR1, as well as provide funding for discovery research activities conducted or managed by STORM. Exelixis will be solely responsible for global development, manufacturing and commercialization activities of any resulting molecules. STORM will be eligible for development, regulatory and commercialization milestones, as well as tiered royalties on the annual net sales of any compounds that are successfully commercialized under the collaboration.

ShowHide Related Items >><<
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

Hot Stocks
Exelixis in-licenses 2nd anti-cancer compound from Aurigene » 08:09
10/14/21
10/14
08:09
10/14/21
08:09
EXEL

Exelixis

$21.46 /

+0.065 (+0.30%)

Exelixis announced that…

Exelixis announced that Exelixis has exercised its exclusive option under the companies' July 2019 agreement to in-license XL114 a novel anti-cancer compound that inhibits the CARD11-BCL10-MALT1 signaling pathway, which promotes lymphocyte survival and proliferation. Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114. Following the U.S. Food and Drug Administration's recent acceptance of its Investigational New Drug application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkin's lymphoma. At the American Association of Cancer Research Annual Meeting in April of this year, Aurigene presented preclinical data demonstrating that XL114 exhibited potent anti-proliferative activity in a large panel of cancer cell lines ranging from hematological cancers to solid tumors with excellent selectivity over normal cells. In addition, oral dosing of XL114 resulted in significant dose-dependent tumor growth inhibition in diffuse large B-cell lymphoma and colon carcinoma models. "We are pleased that our agreement with Aurigene has generated a second promising compound that warrants advancement into clinical development and believe the collaboration will continue to play an important role in expanding our pipeline," said Peter Lamb, Ph.D., Executive Vice President, Scientific Strategy and Chief Scientific Officer, Exelixis. "XL114 has shown potent anti-proliferative activity in lymphoma cell lines that have aberrant activation of the CBM signaling pathway and may have a differentiated profile and potential as a best-in-class molecule that could improve outcomes for patients with Non-Hodgkin's lymphoma and other hematologic cancers."

ShowHide Related Items >><<
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

Hot Stocks
Exelixis and STORM Therapeutics announce pact to advance drug leads for cancer » 08:05
10/14/21
10/14
08:05
10/14/21
08:05
EXEL

Exelixis

$21.46 /

+0.065 (+0.30%)

Exelixis and STORM…

Exelixis and STORM Therapeutics announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. Under the terms of the agreement, Exelixis will pay STORM an upfront fee of $17M in exchange for licensing two of STORM's discovery programs targeting RNA modifying enzymes, including ADAR1, as well as provide funding for discovery research activities conducted or managed by STORM. Exelixis will be solely responsible for global development, manufacturing and commercialization activities of any resulting molecules. STORM will be eligible for development, regulatory and commercialization milestones, as well as tiered royalties on the annual net sales of any compounds that are successfully commercialized under the collaboration. "ADAR1 holds tremendous promise as a novel target for cancer. However, discovery efforts to identify ADAR1 inhibitors have remained a challenge, notably the development of rigorous, relevant assays to support small molecule drug discovery," said Peter Lamb, Ph.D., Executive Vice President, Scientific Strategy and Chief Scientific Officer, Exelixis. "STORM has extensive expertise in RNA-modifying enzymes and has successfully developed advanced mass spectrometry-based high-throughput screening assays and implemented a suite of technologies to enable the discovery of ADAR1 inhibitors. We believe this collaboration has the potential to expand our portfolio of differentiated small molecule therapies in the field of oncology and deliver a first-in-class ADAR1 inhibitor."

ShowHide Related Items >><<
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

10/06/21 Jefferies
Exelixis initiated with a Buy at Jefferies
08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

EXEL Exelixis
$21.46 /

+0.065 (+0.30%)

Initiation
Exelixis initiated with a Buy at Jefferies » 16:24
10/06/21
10/06
16:24
10/06/21
16:24
EXEL

Exelixis

$20.89 /

-0.035 (-0.17%)

Jefferies analyst Akash…

Jefferies analyst Akash Tewari initiated coverage of Exelixis with a Buy rating and $28 price target. The analyst said that, despite recent clinical setbacks, Exelixis is one of the "most interesting" IP plays in SMID cap heading into next year. Tewari is bullish on Cabometyx's polymorph IP going out to 2030, which could add 30% to the stock, he said.

ShowHide Related Items >><<
EXEL Exelixis
$20.89 /

-0.035 (-0.17%)

EXEL Exelixis
$20.89 /

-0.035 (-0.17%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$20.89 /

-0.035 (-0.17%)

EXEL Exelixis
$20.89 /

-0.035 (-0.17%)

Over a month ago
On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:09
09/20/21
09/20
12:09
09/20/21
12:09
PFE

Pfizer

$44.26 /

+0.37 (+0.84%)

, BNTX

BioNTech

$347.52 /

-11.23 (-3.13%)

, BRKS

Brooks Automation

$101.56 /

+7.47 (+7.94%)

, TWTR

Twitter

$60.03 /

-2.44 (-3.91%)

, DHI

D.R. Horton

$88.03 /

-2.75 (-3.03%)

, COIN

Coinbase

$232.35 /

-12.84 (-5.24%)

, DAL

Delta Air Lines

$40.20 /

+0.1 (+0.25%)

, UAL

United Airlines

$44.68 /

+0.15 (+0.34%)

, JBLU

JetBlue

$15.27 /

+0.045 (+0.30%)

, AAL

American Airlines

$20.06 /

+0.33 (+1.67%)

, LUV

Southwest

$49.00 /

-0.1 (-0.20%)

, ALK

Alaska Air

$56.28 /

-0.66 (-1.16%)

, DIDI

Didi

$7.74 /

-0.55 (-6.63%)

, TRIP

TripAdvisor

$33.56 /

-2.22 (-6.20%)

, FB

Facebook

$353.42 /

-11.13 (-3.05%)

, MDLZ

Mondelez

$60.78 /

-0.17 (-0.28%)

, SYBX

Synlogic

$3.60 /

+0.35 (+10.77%)

, VSTM

Verastem

$2.85 /

+0.09 (+3.27%)

, AMGN

Amgen

$217.14 /

-2.45 (-1.12%)

, SDC

SmileDirectClub

$6.84 /

+0.135 (+2.01%)

, TDOC

Teladoc

$136.96 /

-6.42 (-4.48%)

, EXEL

Exelixis

$19.76 /

-0.975 (-4.70%)

, CGNT

Cognyte

$24.46 /

-3.71 (-13.17%)

, ADGI

Adagio Therapeutics

$49.98 /

-1.02 (-2.00%)

, PSNL

Personalis

$21.52 /

-0.93 (-4.14%)

, MOH

Molina Healthcare

$276.86 /

-1.68 (-0.60%)

, MDGS

Medigus

$1.51 /

+0.03 (+2.03%)

, TXN

Texas Instruments

$191.95 /

-4.38 (-2.23%)

, NVS

Novartis

$83.01 /

-0.48 (-0.57%)

, TDC

Teradata

$52.86 /

+2.26 (+4.47%)

, OTLY

Oatly Group

$16.13 /

-0.16 (-0.98%)

, DNA

Ginkgo Bioworks

$11.24 /

-0.84 (-6.95%)

Get caught up quickly on…

ShowHide Related Items >><<
VSTM Verastem
$2.85 /

+0.09 (+3.27%)

UAL United Airlines
$44.68 /

+0.15 (+0.34%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

TWTR Twitter
$60.03 /

-2.44 (-3.91%)

TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

TDC Teradata
$52.86 /

+2.26 (+4.47%)

SYBX Synlogic
$3.60 /

+0.35 (+10.77%)

SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

PSNL Personalis
$21.52 /

-0.93 (-4.14%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

NVS Novartis
$83.01 /

-0.48 (-0.57%)

MOH Molina Healthcare
$276.86 /

-1.68 (-0.60%)

MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

MDGS Medigus
$1.51 /

+0.03 (+2.03%)

LUV Southwest
$49.00 /

-0.1 (-0.20%)

JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

FB Facebook
$353.42 /

-11.13 (-3.05%)

EXEL Exelixis
$19.76 /

-0.975 (-4.70%)

DNA Ginkgo Bioworks
$11.24 /

-0.84 (-6.95%)

DIDI Didi
$7.74 /

-0.55 (-6.63%)

DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

COIN Coinbase
$232.35 /

-12.84 (-5.24%)

BRKS Brooks Automation
$101.56 /

+7.47 (+7.94%)

BNTX BioNTech
$347.52 /

-11.23 (-3.13%)

AMGN Amgen
$217.14 /

-2.45 (-1.12%)

ALK Alaska Air
$56.28 /

-0.66 (-1.16%)

ADGI Adagio Therapeutics
$49.98 /

-1.02 (-2.00%)

AAL American Airlines
$20.06 /

+0.33 (+1.67%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Evercore ISI doesn't think FDA panel will recommend COVID-19 boosters
09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
BNTX BioNTech
$347.52 /

-11.23 (-3.13%)

08/27/21 UBS
BioNTech price target raised to $300 from $111 at UBS
08/20/21 Canaccord
BioNTech price target raised to $450 from $240 at Canaccord
08/12/21 Wells Fargo
Wells says Moderna vaccine looks more effective than Pfizer's against Delta
BRKS Brooks Automation
$101.56 /

+7.47 (+7.94%)

09/07/21 KeyBanc
Brooks Automation price target raised to $146 from $115 at KeyBanc
05/11/21 Needham
Brooks Automation price target raised to $130 from $110 at Needham
05/11/21 Credit Suisse
Brooks Automation price target raised to $85 from $70 at Credit Suisse
05/11/21 B. Riley
Brooks Automation price target raised to $130 from $125 at B. Riley
TWTR Twitter
$60.03 /

-2.44 (-3.91%)

09/13/21
Fly Intel: Top five analyst initiations
09/13/21 Goldman Sachs
Twitter initiated with a Sell at Goldman Sachs
09/09/21 JPMorgan
Netflix, Uber added as top U.S. Internet picks at JPMorgan
08/23/21 Arete
Arete sees 'various hurdles' for Twitter to hit 2023 sales target
DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

07/26/21
Fly Intel: Top five analyst upgrades
07/26/21 Wedbush
D.R. Horton upgraded to Outperform at Wedbush
07/26/21 Wedbush
D.R. Horton upgraded to Outperform from Neutral at Wedbush
07/23/21
Fly Intel: Top five analyst upgrades
COIN Coinbase
$232.35 /

-12.84 (-5.24%)

09/14/21 Piper Sandler
Coinbase recent selloff overdone, says Piper Sandler
09/08/21 Cowen
SEC's Coinbase action likely a broader crackdown on crypto lending, says Cowen
08/24/21
Fly Intel: Top five analyst initiations
08/24/21 Needham
Coinbase initiated with Buy, $420 price target at Needham
DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

08/11/21 Redburn
Delta Air Lines initiated with a Neutral at Redburn
07/15/21 Morgan Stanley
Delta shares deserve to be trading 'significantly higher,' says Morgan Stanley
07/15/21
Fly Intel: Top five analyst upgrades
07/15/21 Susquehanna
Delta Air Lines price target lowered to $45 from $53 at Susquehanna
UAL United Airlines
$44.68 /

+0.15 (+0.34%)

08/11/21 Redburn
United Airlines initiated with a Sell at Redburn
07/22/21 MKM Partners
United Airlines price target lowered to $61 from $65 at MKM Partners
07/22/21 Susquehanna
United Airlines price target lowered to $51 from $56 at Susquehanna
07/13/21
Fly Intel: Top five analyst downgrades
JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

07/28/21 Susquehanna
JetBlue price target lowered to $21 from $24 at Susquehanna
06/09/21 MKM Partners
JetBlue initiated with a Neutral at MKM Partners
06/09/21 MKM Partners
JetBlue initiated with a Neutral at MKM Partners
04/15/21 Barclays
JetBlue price target raised to $20 from $14 at Barclays
AAL American Airlines
$20.06 /

+0.33 (+1.67%)

08/11/21 Redburn
American Airlines initiated with a Buy at Redburn
07/27/21
Fly Intel: Top five analyst upgrades
07/27/21 Susquehanna
American Airlines upgraded to Neutral at Susquehanna
07/27/21 Susquehanna
American Airlines upgraded to Neutral from Negative at Susquehanna
LUV Southwest
$49.00 /

-0.1 (-0.20%)

09/10/21 Evercore ISI
Southwest price target lowered to $62 from $70 at Evercore ISI
08/12/21 Morgan Stanley
Southwest price target lowered to $80 from $85 at Morgan Stanley
08/11/21 Redburn
Southwest initiated with a Buy at Redburn
07/27/21 Berenberg
American Airlines upgraded to Hold from Sell at Berenberg
ALK Alaska Air
$56.28 /

-0.66 (-1.16%)

07/20/21 Raymond James
Alaska Air price target lowered to $78 from $85 at Raymond James
07/12/21 Evercore ISI
Volaris price target raised to $30 from $25 at Evercore ISI
06/18/21 Wolfe Research
Wolfe Research upgrades three airlines on 'pent-up demand scenario'
06/18/21 Wolfe Research
Alaska Air upgraded to Outperform from Peer Perform at Wolfe Research
DIDI Didi
$7.74 /

-0.55 (-6.63%)

07/28/21 Alliance Global Partners
Alliance Global Partners bullish on Aurora Mobile despite regulatory changes
07/28/21 Alliance Global Partners
iClick Interactive price target lowered to $15 from $21 at Alliance Global
07/26/21 Atlantic Equities
Atlantic Equities downgrades DiDi to Neutral amid active investigations
07/26/21 Atlantic Equities
DiDi downgraded to Neutral from Overweight at Atlantic Equities
TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

09/20/21 BTIG
BTIG says TripAdvisor's reported Plus pivot 'feels like a pretty big concession'
08/18/21 DA Davidson
TripAdvisor price target raised to $48 from $47 at DA Davidson
06/16/21 Truist
TripAdvisor rolls out subscription product 'on schedule,' says Truist
06/14/21 Ascendiant
TripAdvisor price target raised to $54 from $50 at Ascendiant
FB Facebook
$353.42 /

-11.13 (-3.05%)

09/17/21 Jefferies
Facebook price target raised to $440 from $425 at Jefferies
09/13/21 Goldman Sachs
Facebook initiated with a Buy at Goldman Sachs
09/09/21 HSBC
Facebook price target raised to $300 from $275 at HSBC
MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 Goldman Sachs
Mondelez downgraded to Buy from Conviction Buy at Goldman Sachs
07/19/21 Morgan Stanley
Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
07/19/21 Deutsche Bank
Mondelez price target raised to $71 from $70 at Deutsche Bank
SYBX Synlogic
$3.60 /

+0.35 (+10.77%)

07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
VSTM Verastem
$2.85 /

+0.09 (+3.27%)

07/01/21 Alliance Global Partners
Verastem initiated with a Buy at Alliance Global Partners
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
AMGN Amgen
$217.14 /

-2.45 (-1.12%)

09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Amgen to Equal Weight, sees better risk/reward elsewhere
09/07/21 Morgan Stanley
Amgen downgraded to Equal Weight from Overweight at Morgan Stanley
08/12/21 Goldman Sachs
Revolution Medicines downgraded to Neutral from Buy at Goldman Sachs
SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Wolfe Research
SmileDirectClub downgraded to Peer Perform from Outperform at Wolfe Research
08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 Loop Capital
SmileDirectClub price target lowered to $6 from $9 at Loop Capital
TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

09/20/21 KeyBanc
New CEO 'certainly a positive surprise' for NextGen shareholders, says KeyBanc
09/15/21 RBC Capital
Teladoc long-term growth outlook intact, says RBC Capital
08/09/21 Cowen
Teladoc price target lowered to $188 from $240 at Cowen
08/02/21
Fly Intel: Top five analyst downgrades
EXEL Exelixis
$19.76 /

-0.975 (-4.70%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
CGNT Cognyte
$24.46 /

-3.71 (-13.17%)

07/27/21 William Blair
Cognyte initiated with an Outperform at William Blair
07/26/21 William Blair
Cognyte initiated with an Outperform at William Blair
03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Evercore ISI
Cognyte initiated with an Outperform at Evercore ISI
ADGI Adagio Therapeutics
$49.98 /

-1.02 (-2.00%)

08/31/21
Fly Intel: Top five analyst initiations
08/31/21 Guggenheim
Adagio Therapeutics initiated with a Buy at Guggenheim
08/31/21 Stifel
Adagio Therapeutics initiated with a Buy at Stifel
08/31/21 Jefferies
Adagio Therapeutics initiated with a Buy at Jefferies
PSNL Personalis
$21.52 /

-0.93 (-4.14%)

09/20/21 Citi
Personalis Veterans Affairs contract smaller than expected, says Citi
08/05/21 Citi
Personalis price target lowered to $30 from $37 at Citi
05/13/21 Truist
Personalis price target lowered to $29 from $37 at Truist
05/06/21 Oppenheimer
Personalis upgraded to Outperform at Oppenheimer on multi-year growth cycle
MOH Molina Healthcare
$276.86 /

-1.68 (-0.60%)

09/20/21 Truist
Molina Healthcare price target raised to $330 from $300 at Truist
09/20/21 Credit Suisse
Molina Healthcare price target raised to $318 from $280 at Credit Suisse
09/20/21 Stephens
Molina Healthcare price target raised to $280 from $260 at Stephens
09/20/21 Mizuho
Molina Healthcare price target raised to $305 from $284 at Mizuho
MDGS Medigus
$1.51 /

+0.03 (+2.03%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

09/20/21
Fly Intel: Top five analyst downgrades
09/20/21 Longbow
Texas Instruments downgraded to Neutral from Buy at Longbow
07/22/21
Fly Intel: Top five analyst downgrades
07/22/21 Raymond James
Texas Instruments price target raised to $230 from $220 at Raymond James
NVS Novartis
$83.01 /

-0.48 (-0.57%)

09/20/21 Deutsche Bank
Novartis downgraded to Sell from Hold at Deutsche Bank
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 Wedbush
Wedbush downgrades Xoma to Neutral, cuts target to $22
07/28/21 JPMorgan
Novartis price target raised to CHF 84 from CHF 80 at JPMorgan
TDC Teradata
$52.86 /

+2.26 (+4.47%)

09/20/21 Morgan Stanley
Morgan Stanley ups Teradata to Overweight, says Cloud business underappreciated
09/20/21 Morgan Stanley
Teradata upgraded to Overweight from Equal Weight at Morgan Stanley
09/10/21 JMP Securities
Teradata price target raised to $78 from $70 at JMP Securities
09/08/21 Stifel
Stifel says Parker-Hannifin's Meggitt bid has 'smoother route' with Teradata out
OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

09/20/21
Fly Intel: Top five analyst initiations
09/20/21 Citi
Oatly Group initiated with a Buy at Citi
09/10/21 Cowen
Cowen starts Oatly at Outperform, says 'punching above its weight'
09/10/21 Cowen
Oatly Group initiated with an Outperform at Cowen
DNA Ginkgo Bioworks
$11.24 /

-0.84 (-6.95%)

09/20/21 HSBC
Ginkgo Bioworks initiated with a Buy at HSBC
VSTM Verastem
$2.85 /

+0.09 (+3.27%)

UAL United Airlines
$44.68 /

+0.15 (+0.34%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

TWTR Twitter
$60.03 /

-2.44 (-3.91%)

TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

TDC Teradata
$52.86 /

+2.26 (+4.47%)

SYBX Synlogic
$3.60 /

+0.35 (+10.77%)

SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

PSNL Personalis
$21.52 /

-0.93 (-4.14%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

NVS Novartis
$83.01 /

-0.48 (-0.57%)

MOH Molina Healthcare
$276.86 /

-1.68 (-0.60%)

MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

MDGS Medigus
$1.51 /

+0.03 (+2.03%)

LUV Southwest
$49.00 /

-0.1 (-0.20%)

JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

FB Facebook
$353.42 /

-11.13 (-3.05%)

EXEL Exelixis
$19.76 /

-0.975 (-4.70%)

DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

COIN Coinbase
$232.35 /

-12.84 (-5.24%)

CGNT Cognyte
$24.46 /

-3.71 (-13.17%)

BRKS Brooks Automation
$101.56 /

+7.47 (+7.94%)

BNTX BioNTech
$347.52 /

-11.23 (-3.13%)

AMGN Amgen
$217.14 /

-2.45 (-1.12%)

ALK Alaska Air
$56.28 /

-0.66 (-1.16%)

ADGI Adagio Therapeutics
$49.98 /

-1.02 (-2.00%)

AAL American Airlines
$20.06 /

+0.33 (+1.67%)

  • 06
    Aug
  • 30
    Jun
  • 20
    May
  • 16
    Apr
  • 14
    Apr
  • 27
    Jan
  • 11
    Jan
  • 02
    Dec
  • 02
    Dec
  • 24
    Nov
  • 19
    Nov
  • 10
    Nov
UAL United Airlines
$44.68 /

+0.15 (+0.34%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

TWTR Twitter
$60.03 /

-2.44 (-3.91%)

TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

NVS Novartis
$83.01 /

-0.48 (-0.57%)

MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

LUV Southwest
$49.00 /

-0.1 (-0.20%)

JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

FB Facebook
$353.42 /

-11.13 (-3.05%)

DIDI Didi
$7.74 /

-0.55 (-6.63%)

DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

COIN Coinbase
$232.35 /

-12.84 (-5.24%)

BRKS Brooks Automation
$101.56 /

+7.47 (+7.94%)

BNTX BioNTech
$347.52 /

-11.23 (-3.13%)

AAL American Airlines
$20.06 /

+0.33 (+1.67%)

VSTM Verastem
$2.85 /

+0.09 (+3.27%)

UAL United Airlines
$44.68 /

+0.15 (+0.34%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

TWTR Twitter
$60.03 /

-2.44 (-3.91%)

TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

TDC Teradata
$52.86 /

+2.26 (+4.47%)

SYBX Synlogic
$3.60 /

+0.35 (+10.77%)

SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

PSNL Personalis
$21.52 /

-0.93 (-4.14%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

NVS Novartis
$83.01 /

-0.48 (-0.57%)

MOH Molina Healthcare
$276.86 /

-1.68 (-0.60%)

MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

LUV Southwest
$49.00 /

-0.1 (-0.20%)

JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

FB Facebook
$353.42 /

-11.13 (-3.05%)

EXEL Exelixis
$19.76 /

-0.975 (-4.70%)

DNA Ginkgo Bioworks
$11.24 /

-0.84 (-6.95%)

DIDI Didi
$7.74 /

-0.55 (-6.63%)

DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

COIN Coinbase
$232.35 /

-12.84 (-5.24%)

CGNT Cognyte
$24.46 /

-3.71 (-13.17%)

BRKS Brooks Automation
$101.56 /

+7.47 (+7.94%)

AMGN Amgen
$217.14 /

-2.45 (-1.12%)

ALK Alaska Air
$56.28 /

-0.66 (-1.16%)

ADGI Adagio Therapeutics
$49.98 /

-1.02 (-2.00%)

AAL American Airlines
$20.06 /

+0.33 (+1.67%)

UAL United Airlines
$44.68 /

+0.15 (+0.34%)

TXN Texas Instruments
$191.95 /

-4.38 (-2.23%)

TWTR Twitter
$60.03 /

-2.44 (-3.91%)

TRIP TripAdvisor
$33.56 /

-2.22 (-6.20%)

TDOC Teladoc
$136.96 /

-6.42 (-4.48%)

TDC Teradata
$52.86 /

+2.26 (+4.47%)

SDC SmileDirectClub
$6.84 /

+0.135 (+2.01%)

PFE Pfizer
$44.26 /

+0.37 (+0.84%)

OTLY Oatly Group
$16.13 /

-0.16 (-0.98%)

MDLZ Mondelez
$60.78 /

-0.17 (-0.28%)

LUV Southwest
$49.00 /

-0.1 (-0.20%)

JBLU JetBlue
$15.27 /

+0.045 (+0.30%)

FB Facebook
$353.42 /

-11.13 (-3.05%)

DNA Ginkgo Bioworks
$11.24 /

-0.84 (-6.95%)

DIDI Didi
$7.74 /

-0.55 (-6.63%)

DHI D.R. Horton
$88.03 /

-2.75 (-3.03%)

DAL Delta Air Lines
$40.20 /

+0.1 (+0.25%)

COIN Coinbase
$232.35 /

-12.84 (-5.24%)

AMGN Amgen
$217.14 /

-2.45 (-1.12%)

AAL American Airlines
$20.06 /

+0.33 (+1.67%)

Hot Stocks
Exelixis announces results from Phase 3 COSMIC-311 trial of CABOMETYX » 11:38
09/20/21
09/20
11:38
09/20/21
11:38
EXEL

Exelixis

$19.68 /

-1.055 (-5.09%)

Exelixis announced final…

Exelixis announced final results from the phase 3 COSMIC-311 pivotal trial of CABOMETYX in patients with previously treated radioactive iodine-refractory differentiated thyroid cancer. Following a previous announcement that the trial met one of the two primary endpoints of significant improvement versus placebo in progression-free survival assessed by blinded independent radiology committee, the results of the final analysis are being presented during the Mini Oral Session - NETs and Endocrine Tumours at 5:30 p.m. CEST on Monday, September 20 at the 2021 European Society of Medical Oncology Congress . At a median follow-up of 10.1 months, the significant improvement in PFS with CABOMETYX was maintained, with consistent benefit in subgroups based on prior treatment. At a median follow-up of 10.1 months, CABOMETYX reduced the risk of disease progression or death versus placebo in the intent-to-treat population. Median PFS as assessed by BIRC was 11.0 months for patients treated with CABOMETYX compared with 1.9 months for patients treated with placebo. Subgroup analyses demonstrated that CABOMETYX improved PFS versus placebo irrespective of prior exposure to lenvatinib and/or sorafenib: Prior sorafenib/no lenvatinib: median PFS was 16.6 months for patients treated with CABOMETYX compared with 3.2 months for placebo. Prior lenvatinib/no sorafenib: median PFS was 5.8 months for patients treated with CABOMETYX compared with 1.9 months for placebo. Prior sorafenib and lenvatinib: median PFS was 7.6 months for patients treated with CABOMETYX compared with 1.9 months for placebo.An updated analysis for the primary endpoint of objective response rate as assessed by BIRC in the ITT population favored CABOMETYX at 11%, including one complete response, versus 0% for placebo. Median overall survival, an additional endpoint, was 19.4 months for patients treated with CABOMETYX and not estimable for patients treated with placebo. The safety profile was consistent with that previously observed for CABOMETYX, and adverse events were managed with dose modifications. The discontinuation rate due to treatment-emergent AEs was 8.8% for CABOMETYX versus 0% for placebo. Rates of grade 3/4 treatment-emergent AEs were 62% for CABOMETYX versus 28% for placebo, with no treatment-related deaths. Dose reductions due to AEs were required in 67% of patients treated with CABOMETYX versus 5% for placebo. Results from COSMIC-311 served as the basis for the September 17, 2021 U.S. Food and Drug Administration approval of CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic DTC that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible. The application was approved well ahead of the Prescription Drug User Fee Act target action date of December 4, 2021.

ShowHide Related Items >><<
EXEL Exelixis
$19.68 /

-1.055 (-5.09%)

EXEL Exelixis
$19.68 /

-1.055 (-5.09%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$19.68 /

-1.055 (-5.09%)

EXEL Exelixis
$19.68 /

-1.055 (-5.09%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
09/20/21
09/20
08:55
09/20/21
08:55
SYBX

Synlogic

$3.25 /

+0.06 (+1.88%)

, VSTM

Verastem

$2.76 /

+0.06 (+2.23%)

, SDC

SmileDirectClub

$6.70 /

+0.705 (+11.76%)

, AZN

AstraZeneca

$55.56 /

-1.04 (-1.84%)

, GLBL

Cartesian Growth

$9.75 /

+0.05 (+0.52%)

, CGNT

Cognyte

$28.17 /

+0.245 (+0.88%)

, ADGI

Adagio Therapeutics

$51.51 /

-4.46 (-7.97%)

, TDOC

Teladoc

$143.32 /

+7.13 (+5.24%)

, EXEL

Exelixis

$20.74 /

+0.205 (+1.00%)

, NXGN

NextGen Healthcare

$15.24 /

+0.51 (+3.46%)

Check out this morning's…

ShowHide Related Items >><<
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

SYBX Synlogic
$3.25 /

+0.06 (+1.88%)

SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

NXGN NextGen Healthcare
$15.24 /

+0.51 (+3.46%)

GLBL Cartesian Growth
$9.75 /

+0.05 (+0.52%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ADGI Adagio Therapeutics
$51.51 /

-4.46 (-7.97%)

SYBX Synlogic
$3.25 /

+0.06 (+1.88%)

07/09/21 Chardan
Synlogic assumed with a Buy at Chardan
06/28/21 H.C. Wainwright
Synlogic price target lowered to $9 from $13 at H.C. Wainwright
03/25/21 SVB Leerink
Synlogic price target raised to $15 from $10 at SVB Leerink
03/18/21 JonesTrading
Synlogic initiated with a Buy at JonesTrading
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

07/01/21 Alliance Global Partners
Verastem initiated with a Buy at Alliance Global Partners
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
05/24/21 BTIG
Verastem upgraded to Buy from Neutral at BTIG
SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Wolfe Research
SmileDirectClub downgraded to Peer Perform from Outperform at Wolfe Research
08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 Loop Capital
SmileDirectClub price target lowered to $6 from $9 at Loop Capital
AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/17/21 Evercore ISI
Innate Pharma price target raised to $10 from $6 at Evercore ISI
09/17/21 Morgan Stanley
AstraZeneca price target raised to 10,000 GBp from 9,800 GBp at Morgan Stanley
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
GLBL Cartesian Growth
$9.75 /

+0.05 (+0.52%)

CGNT Cognyte
$28.17 /

+0.245 (+0.88%)

07/27/21 William Blair
Cognyte initiated with an Outperform at William Blair
07/26/21 William Blair
Cognyte initiated with an Outperform at William Blair
03/05/21
Fly Intel: Top five analyst initiations
03/05/21 Evercore ISI
Cognyte initiated with an Outperform at Evercore ISI
ADGI Adagio Therapeutics
$51.51 /

-4.46 (-7.97%)

08/31/21
Fly Intel: Top five analyst initiations
08/31/21 Guggenheim
Adagio Therapeutics initiated with a Buy at Guggenheim
08/31/21 Stifel
Adagio Therapeutics initiated with a Buy at Stifel
08/31/21 Jefferies
Adagio Therapeutics initiated with a Buy at Jefferies
TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

09/15/21 RBC Capital
Teladoc long-term growth outlook intact, says RBC Capital
08/09/21 Cowen
Teladoc price target lowered to $188 from $240 at Cowen
08/02/21
Fly Intel: Top five analyst downgrades
08/02/21 Argus
Teladoc downgraded to Hold at Argus on continued operating losses
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
NXGN NextGen Healthcare
$15.24 /

+0.51 (+3.46%)

06/21/21 Piper Sandler
Piper says NextGen Healthcare CEO resignation won't change market share gains
05/27/21 Piper Sandler
NextGen Healthcare price target lowered to $23 from $24 at Piper Sandler
04/29/21 JPMorgan
NextGen Healthcare resumed with an Underweight at JPMorgan
03/15/21 Piper Sandler
NextGen analyst day will be positive for shares, says Piper Sandler
VSTM Verastem
$2.76 /

+0.06 (+2.23%)

TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

SYBX Synlogic
$3.25 /

+0.06 (+1.88%)

SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

NXGN NextGen Healthcare
$15.24 /

+0.51 (+3.46%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

CGNT Cognyte
$28.17 /

+0.245 (+0.88%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ADGI Adagio Therapeutics
$51.51 /

-4.46 (-7.97%)

  • 06
    Aug
  • 16
    Apr
  • 24
    Nov
  • 19
    Nov
TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

GLBL Cartesian Growth
$9.75 /

+0.05 (+0.52%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

VSTM Verastem
$2.76 /

+0.06 (+2.23%)

TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

SYBX Synlogic
$3.25 /

+0.06 (+1.88%)

SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

NXGN NextGen Healthcare
$15.24 /

+0.51 (+3.46%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

CGNT Cognyte
$28.17 /

+0.245 (+0.88%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

ADGI Adagio Therapeutics
$51.51 /

-4.46 (-7.97%)

TDOC Teladoc
$143.32 /

+7.13 (+5.24%)

SDC SmileDirectClub
$6.70 /

+0.705 (+11.76%)

AZN AstraZeneca
$55.56 /

-1.04 (-1.84%)

Hot Stocks
Exelixis announces detailed Phase 1b results from cohort 6 of COSMIC-021 trial » 14:42
09/19/21
09/19
14:42
09/19/21
14:42
EXEL

Exelixis

$20.74 /

+0.205 (+1.00%)

Exelixis announced…

Exelixis announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer. Cohort 6 included patients with metastatic CRPC who had been previously treated with the novel hormone therapies enzalutamide and/or abiraterone acetate used along with prednisone. Eligible patients in the trial had measurable disease per Response Evaluation Criteria in Solid Tumors per investigator assessment, had progressed on prior NHT, and could have received prior docetaxel for metastatic hormone-sensitive disease. The analysis included 132 patients with metastatic CRPC, 101 of whom were high-risk, which was defined as having measurable visceral metastases and/or extrapelvic lymphadenopathy. The median follow-up for all patients was 15.2 months, and the primary endpoint was objective response rate by investigator per RECIST 1.1. As previously announced, in the high-risk patient population, investigator-assessed ORR was 27%, including 2% complete responses. The Blinded Independent Radiology Committee-assessed ORR was 18%, all partial responses. The disease control rate was 88% by investigator assessment and 84% by BIRC assessment. New detailed results being presented at the 2021 ESMO Congress demonstrate that median progression-free survival per RECIST 1.1 for the high-risk population was 5.6 months as assessed by investigators and 6.8 months as assessed by BIRC. The exploratory endpoint of overall survival for the high-risk patient population was 18.4 months. Tumor PD-L1 status, which was known for 75 patients, was not associated with response. The safety profile was consistent with that previously observed for each single agent. No new safety signals were observed. Discontinuation of both agents due to treatment-related adverse events occurred in 10% of patients. Frequent treatment-related AEs were diarrhea, fatigue, nausea and decreased appetite. Grade 3 or 4 treatment-related AEs occurred in 55% of patients, and one grade 5 treatment-related AE was reported. Following discussions with the U.S. Food and Drug Administration, Exelixis will not pursue a regulatory submission for the combination regimen based on cohort 6 of the COSMIC-021 trial. The CONTACT-02 study, a global phase 3 pivotal trial, initiated enrollment in June 2020 and is evaluating cabozantinib in combination with atezolizumab versus a second NHT in patients with metastatic CRPC who have been previously treated with one NHT. Pending results, CONTACT-02 may serve as a basis for future regulatory applications in this setting.

ShowHide Related Items >><<
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

Hot Stocks
Exelixis announces FDA approval of CABOMETYX » 16:24
09/17/21
09/17
16:24
09/17/21
16:24
EXEL

Exelixis

$20.74 /

+0.205 (+1.00%)

Exelixis announced that…

Exelixis announced that the U.S. FDA approved CABOMETYX for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible. The FDA granted Breakthrough Therapy designation and Priority Review to CABOMETYX and its approval comes more than two months ahead of the Prescription Drug User Fee Act target action date of December 4, 2021.

ShowHide Related Items >><<
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

EXEL Exelixis
$20.74 /

+0.205 (+1.00%)

Conference/Events
BofA to hold a virtual conference » 04:55
09/17/21
09/17
04:55
09/17/21
04:55
RHHBY

Roche

$46.82 /

-0.04 (-0.09%)

, ALLO

Allogene Therapeutics

$24.53 /

-0.42 (-1.68%)

, ATR

AptarGroup

$122.29 /

-2.415 (-1.94%)

, FMS

Fresenius Medical

$35.31 /

-0.36 (-1.01%)

, SNY

Sanofi

$48.20 /

+0.185 (+0.39%)

, WAT

Waters

$399.60 /

-10.23 (-2.50%)

, ALNY

Alnylam

$190.23 /

+2.63 (+1.40%)

, BLUE

Bluebird Bio

$17.67 /

-0.12 (-0.67%)

, AZN

AstraZeneca

$56.60 /

+0.14 (+0.25%)

, EXEL

Exelixis

$20.53 /

+0.04 (+0.20%)

, FOLD

Amicus

$11.09 /

-0.06 (-0.54%)

, PFE

Pfizer

$44.46 /

-0.31 (-0.69%)

, PAHC

Phibro Animal Health

$21.32 /

-0.08 (-0.37%)

, QGEN

Qiagen

$54.15 /

+0.6601 (+1.23%)

, IONS

Ionis Pharmaceuticals

$36.45 /

-0.55 (-1.49%)

Global Healthcare Virtual…

Global Healthcare Virtual Conference to be held on September 15-17.

ShowHide Related Items >><<
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/07/21 UBS
Roche price target raised to CHF 350 from CHF 345 at UBS
08/02/21 JPMorgan
Roche price target raised to CHF 360 from CHF 310 at JPMorgan
07/27/21 Societe Generale
Roche price target raised to CHF 353 from CHF 340 at Societe Generale
ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

08/06/21 B. Riley
Allogene Therapeutics price target lowered to $40 from $52 at B. Riley
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
08/05/21 Oppenheimer
Allogene Therapeutics price target lowered to $44 from $52 at Oppenheimer
06/21/21 Jefferies
Allogene Therapeutics assumed with a Buy at Jefferies
ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

09/13/21 Baird
AptarGroup price target lowered to $135 from $150 at Baird
08/02/21 William Blair
William Blair downgrades AptarGroup after 'underwhelming quarter'
08/02/21 William Blair
AptarGroup downgraded to Market Perform from Outperform at William Blair
04/19/21 Deutsche Bank
AptarGroup price target raised to $162 from $152 at Deutsche Bank
FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

09/10/21 Barclays
Fresenius Medical downgraded to Equal Weight from Overweight at Barclays
09/10/21 JPMorgan
Fresenius Medical downgraded to Underweight from Neutral at JPMorgan
08/11/21 JPMorgan
Fresenius Medical price target raised to EUR 61.30 from EUR 58.80 at JPMorgan
08/04/21 Societe Generale
Fresenius Medical price target raised to EUR 71 from EUR 64 at Societe Generale
SNY Sanofi
$48.20 /

+0.185 (+0.39%)

09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
WAT Waters
$399.60 /

-10.23 (-2.50%)

08/04/21 SVB Leerink
Waters price target raised to $385 from $370 at SVB Leerink
08/04/21 Baird
Waters price target raised to $360 from $297 at Baird
08/04/21 Citi
Waters price target raised to $400 from $315 at Citi
07/06/21 Evercore ISI
Evercore ISI upgrades Waters to Outperform on turnaround progress
ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

08/27/21 BMO Capital
Alnylam price target raised to $196 from $174 at BMO Capital
08/04/21 Barclays
Alnylam price target raised to $216 from $196 at Barclays
08/04/21 Piper Sandler
Alnylam downgraded to Neutral from Overweight at Piper Sandler
06/30/21 Piper Sandler
Alnylam's zilebesiran has 'best in class' potential, says Piper Sandler
BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

08/12/21 JPMorgan
AstraZeneca resumed with an Overweight at JPMorgan
08/11/21 Goldman Sachs
FibroGen price target lowered to $16 from $22 at Goldman Sachs
08/09/21 Morgan Stanley
AstraZeneca resumed with an Overweight at Morgan Stanley
EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

08/06/21 H.C. Wainwright
Exelixis price target raised to $64 from $35 at H.C. Wainwright
06/29/21 H.C. Wainwright
Exelixis price target lowered to $35 from $47 at H.C. Wainwright
06/29/21 Oppenheimer
Exelixis price target lowered to $27 from $35 at Oppenheimer
06/28/21 Piper Sandler
Exelixis selloff on trial miss an overreaction, says Piper Sandler
FOLD Amicus
$11.09 /

-0.06 (-0.54%)

07/19/21 BTIG
Amicus assumed with a Buy at BTIG
07/09/21 Chardan
Amicus coverage transferred at Chardan
07/01/21 Berenberg
Amicus assumed with a Hold at Berenberg
05/27/21 Needham
Amicus initiated with a Hold at Needham
PFE Pfizer
$44.46 /

-0.31 (-0.69%)

09/16/21 Canaccord
Exact Sciences salesforce expansion a net positive, says Canaccord
09/16/21 BofA
Moderna boosters already reflected in 'bullish' consensus, says BofA
09/15/21 Raymond James
Exact Sciences' 'opportunistic' hires should boost sales, says Raymond James
09/13/21 JPMorgan
Pfizer price target raised to $42 from $40 at JPMorgan
PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

08/04/21 Credit Suisse
Phibro Animal Health assumed with a Neutral at Credit Suisse
07/07/21
Fly Intel: Top five analyst downgrades
07/07/21 Barclays
Phibro Animal Health downgraded to Underweight from Equal Weight at Barclays
QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

07/14/21 Citi
Qiagen price target lowered to $58 from $65 at Citi
07/14/21 Kepler Cheuvreux
Qiagen downgraded to Hold from Buy at Kepler Cheuvreux
06/11/21 Berenberg
Qiagen price target lowered to EUR 54 from EUR 56 at Berenberg
06/03/21 Goldman Sachs
Qiagen initiated with a Neutral at Goldman Sachs
IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

07/15/21 Canaccord
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord
07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
WAT Waters
$399.60 /

-10.23 (-2.50%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

PAHC Phibro Animal Health
$21.32 /

-0.08 (-0.37%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ATR AptarGroup
$122.29 /

-2.415 (-1.94%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

SNY Sanofi
$48.20 /

+0.185 (+0.39%)

RHHBY Roche
$46.82 /

-0.04 (-0.09%)

QGEN Qiagen
$54.15 /

+0.6601 (+1.23%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

FOLD Amicus
$11.09 /

-0.06 (-0.54%)

FMS Fresenius Medical
$35.31 /

-0.36 (-1.01%)

EXEL Exelixis
$20.53 /

+0.04 (+0.20%)

BLUE Bluebird Bio
$17.67 /

-0.12 (-0.67%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

ALNY Alnylam
$190.23 /

+2.63 (+1.40%)

ALLO Allogene Therapeutics
$24.53 /

-0.42 (-1.68%)

PFE Pfizer
$44.46 /

-0.31 (-0.69%)

IONS Ionis Pharmaceuticals
$36.45 /

-0.55 (-1.49%)

AZN AstraZeneca
$56.60 /

+0.14 (+0.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.